Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Louisiana Health Daily.
Press releases published on October 1, 2025
Visory Health genera ahorros de 790 millones de dólares en medicamentos cardiovasculares esenciales
ESTERO, Florida, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Visory Health, una plataforma tecnológica de salud centrada en el paciente que ofrece medicamentos con receta y que está transformando la forma en que los veteranos, las familias y los cuidadores acceden a …
New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk
MELBOURNE, Australia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Imprivata, a leading provider of access management solutions for healthcare and other mission-critical industries, today released new research which finds that each Australian healthcare facility that …
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other …
TOMI Environmental Solutions Appoints Harold W. Paul to Its Board of Directors
FREDERICK, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its …
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek …
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and …
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus 85% (11/13) disease control rate (DCR) 69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial …
NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Le traitement a été bien toléré et la faisabilité de l’injection a été confirmée chez les 13 patients atteints d’adénocarcinome de l’œsophage localement avancé. Le taux de contrôle de la maladie (DCR, disease control rate) était de 85 % (11/13). Le taux de …
Vital Nutrients Expands Clinical Line With New Formula for Women’s Hair Health
MIDDLETOWN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- With female hair loss on the rise, Vital Nutrients is introducing Hair Growth Complex for Women, a clinically formulated supplement targeting the biological drivers behind thinning hair to help women …
POP Biotechnologies Awarded $2.46M NIH Grant for Alzheimer's Immunotherapy
Buffalo, NY , Oct. 01, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mosaic” active immunotherapy against Alzheimer’s disease (AD). …
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …
Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before …
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and …
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr …
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: …
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 116,150 restricted …
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an …
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, …
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent …